HUTCHMED (China) (HMDCF) Cash & Equivalents (2014 - 2026)

HUTCHMED (China) (HMDCF) has reported Cash & Equivalents for 13 consecutive years, with $106.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 3.76% year-over-year to $106.6 million in Q2 2026; TTM through Jun 2026 was $106.6 million, a 3.76% decrease from a year earlier, with the FY2025 full-year figure at $71.3 million, changed N/A from the prior year.
• Cash & Equivalents was $106.6 million for Q2 2026 at HUTCHMED (China), up from $71.3 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $631.0 million in Q4 2022 and troughed at $71.3 million in Q4 2025.
• A 5-year average of $259.2 million and a median of $204.0 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents soared 67.13% in 2022 and plunged 52.3% in 2023, its largest moves.
• Over 5 years, Cash & Equivalents stood at $631.0 million in 2022, then slumped by 64.66% to $223.0 million in 2023, then dropped by 8.54% to $204.0 million in 2024, then slumped by 65.03% to $71.3 million in 2025, then surged by 49.39% to $106.6 million in 2026.
• The last three Cash & Equivalents figures came in at $106.6 million (Q2 2026), $71.3 million (Q4 2025), and $110.7 million (Q2 2025), per Business Quant data.